Localization of ureteral orifices: IM, IV (preferred): Usually 5 mL; doses <5 mL preferred in underweight adults to avoid skin discoloration
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
(For additional information see "Indigo carmine: Pediatric drug information")
Localizing ureteral orifices:
Infants and Children: IM, IV (preferred): <5 mL; to avoid skin discoloration, doses less than the usual adolescent/adult dose of 5 mL necessary
Adolescents: IM, IV (preferred): Usual dose: 5 mL, patients who are small for age may need lower dose (<5 mL) to prevent skin discoloration
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Injection:
Indigo Carmine: 8 mg/mL (5 mL)
Yes
IV: Administer undiluted IV (preferred) or IM. Prior to administration, inspect solution for precipitation and discoloration. Withdraw contents using 5 micron filters only.
Parenteral: IV (preferred) or IM: Withdraw contents using a 5 micron filter needle/straw only. Prior to administration, inspect solution for precipitation and discoloration; administer undiluted.
Localization of ureteral orifices: Localizing ureteral orifices during cystoscopy and ureteral catheterization
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined: Cardiovascular: Bradycardia, hypertension
Postmarketing and/or case reports: AV block (second degree), bronchospasm, hypotension (severe), idiosyncratic reaction, urticaria
Known hypersensitivity to indigotindisulfonate sodium
Concerns related to adverse effects:
• Hypersensitivity reactions: Idiosyncratic drug reactions may occur rarely.
• Pressor effects: Mild pressor effect may occur during use.
Other warnings/precautions:
• Administration: Solution must not be diluted or administered with other solutions prior to injection due to risk for precipitation.
Reproduction studies have not been conducted. Use during pregnancy only if clearly needed.
It is not known if indigotindisulfonate sodium is excreted in breast milk. The manufacturer recommends that caution be exercised when administering indigotindisulfonate sodium to nursing women.
Half-life elimination: IV injection: 4-5 minutes; IM injection: Delayed (compared to IV administration)
Excretion: Urine (usually appears within 10 minutes following IV administration; retains blue color)
